Episode Details
Back to Episodes
Sionna Therapeutics is trying to improve the treatment paradigm for cystic fibrosis by targeting NBD1, a nucleotide binding-domain of the CFTR protein, and restore healthy function for all
Published 10 months ago
Description
CEO Mike Cloonan describes the unmet need for better treatments that exists today in CF, and discusses Sionna's development plans.